Cripto-specific antibodies
AssigneeBiogen Idec MA Inc.
InventorsMichele Sanicola-Nadel, Heather Adkins, Steven Donald Miklasz, Paul Rayhorn, Susan Gail Schiffer, Kevin P. Williams
Life of this patent
Estimating the term…
Abstract
The invention provides Cripto-specific antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and inhibit Cripto activity are provided. Antibodies which bind Cripto and inhibit the interaction between Cripto and ALK4 and/or between Cripto and Activin B are provided. Antibodies which bind Cripto and inhibit tumor growth are also provided. Antibodies which bind Cripto, inhibit Cripto activity, and inhibit tumor growth are also provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
Claims32
A method of inhibiting angiogenesis of tumor cells in vivo comprising administering an antibody that specifically binds to an epitope comprised in the cysteine-rich domain of Cripto spanning from amino acid residue 114 to amino acid residue 150 of SEQ ID NO:1 or amino acid residue 114 to amino acid residue 150 of SEQ ID NO:2, wherein the antibody blocks the interaction of Cripto with Activin B and/or Alk4, to a subject having a tumor in an amount sufficient to inhibit angiogenesis such that angiogenesis is inhibited.
A method of inhibiting the growth of tumor cells in vivo comprising administering an antibody that specifically binds to an epitope comprised in the cysteine-rich domain of Cripto spanning from amino acid residue 114 to amino acid residue 150 of SEQ ID NO:1 or amino acid residue 114 to amino acid residue 150 of SEQ ID NO:2, wherein the antibody blocks the interaction of Cripto with Activin B and/or Alk4, to a subject having a tumor.
Dependencies are inferred from the claim text.